QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM)

被引:17
|
作者
Qin, Zijian [1 ]
Wang, Maolin [1 ]
Yan, Aixia [1 ]
机构
[1] Beijing Univ Chem Technol, Dept Pharmaceut Engn, State Key Lab Chem Resource Engn, POB 53,15 BeiSanHuan East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatitis C virus (HCV) NS3/4A protease inhibitors; Quantitative structure-activity relationship (QSAR); Kohonen's self-organizing map (SOM); Multiple linear regression (MLR); Support vector machine (SVM); Sub-dataset analysis; PEPTIDE-BASED INHIBITORS; ALPHA-KETOAMIDES; SERINE-PROTEASE; ANTIVIRAL ACTIVITY; POTENT INHIBITORS; CRYSTAL-STRUCTURE; DISCOVERY; DESIGN; PROTEINASE; BINDING;
D O I
10.1016/j.bmcl.2017.05.001
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this study, quantitative structure-activity relationship (QSAR) models using various descriptor sets and training/test set selection methods were explored to predict the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by using a multiple linear regression (MLR) and a support vector machine (SVM) method. 512 HCV NS3/4A protease inhibitors and their IC50 values which were determined by the same FRET assay were collected from the reported literature to build a dataset. All the inhibitors were represented with selected nine global and 12 2D property-weighted autocorrelation descriptors calculated from the program CORINA Symphony. The dataset was divided into a training set and a test set by a random and a Kohonen's self-organizing map (SOM) method. The correlation coefficients (r(2)) of training sets and test sets were 0.75 and 0.72 for the best MLR model, 0.87 and 0.85 for the best SVM model, respectively. In addition, a series of sub-dataset models were also developed. The performances of all the best sub-dataset models were better than those of the whole dataset models. We believe that the combination of the best sub-and whole dataset SVM models can be used as reliable lead designing tools for new NS3/4A protease inhibitors scaffolds in a drug discovery pipeline. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2931 / 2938
页数:8
相关论文
共 50 条
  • [1] Hepatitis C virus NS3/4a protease inhibitors
    McCauley, John A.
    Rudd, Michael T.
    CURRENT OPINION IN PHARMACOLOGY, 2016, 30 : 84 - 92
  • [2] Classification Models of HCV NS3 Protease Inhibitors Based on Support Vector Machine (SVM)
    Wang, Maolin
    Xuan, Shouyi
    Yan, Aixia
    Yu, Changyuan
    COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2015, 18 (01) : 24 - 32
  • [3] Hepatitis C virus NS3/4A protease
    Kwong, AD
    Kim, JL
    Rao, G
    Lipovsek, D
    Raybuck, SA
    ANTIVIRAL RESEARCH, 1998, 40 (1-2) : 1 - 18
  • [4] Hepatitis C virus NS3/4A protease
    Kwong, AD
    CURRENT OPINION IN INFECTIOUS DISEASES, 1997, 10 (06) : 485 - 490
  • [5] The index of ideality of correlation: QSAR studies of hepatitis C virus NS3/4A protease inhibitors using SMILES descriptors
    Ghiasi, T.
    Ahmadi, S.
    Ahmadi, E.
    Talei Bavil Olyai, M. R.
    Khodadadi, Z.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2021, 32 (06) : 495 - 520
  • [6] Bismacrocyclic Inhibitors of Hepatitis C NS3/4a Protease
    McCauley, John A.
    Rudd, Michael T.
    Nguyen, Kevin T.
    McIntyre, Charles J.
    Romano, Joseph J.
    Bush, Kimberly J.
    Varga, Sandor L.
    Ross, Charles W., III
    Carroll, Steven S.
    DiMuzio, Jillian
    Stahlhut, Mark W.
    Olsen, David B.
    Lyle, Terry A.
    Vacca, Joseph P.
    Liverton, Nigel J.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2008, 47 (47) : 9104 - 9107
  • [7] Novel peptidyl α-aminoalkylphosphonates as inhibitors of hepatitis C virus NS3/4A protease
    Skorenski, Marcin
    Pachota, Magdalena
    Pyrc, Krzysztof
    Sienczyk, Marcin
    Oleksyszyn, Jozef
    ANTIVIRAL RESEARCH, 2017, 144 : 286 - 298
  • [8] Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel
    Chatel-Chaix, Laurent
    Baril, Martin
    Lamarre, Daniel
    VIRUSES-BASEL, 2010, 2 (08): : 1752 - 1765
  • [9] Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors
    Naggie, Susanna
    Patel, Keyur
    McHutchison, John
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) : 2063 - 2069
  • [10] VANIPREVIR HCV NS3/4A Protease Inhibitor Treatment of Hepatitis C
    Hammond, E.
    Lucas, A.
    Lucas, M.
    Phillips, E.
    Gaudieri, S.
    DRUGS OF THE FUTURE, 2010, 35 (10) : 803 - 813